3-甲氧基-5-三氟甲基苯硼酸 | 871332-97-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲氧基-5-三氟甲基苯硼酸
• 中文别名: 3-甲氧基-5-(三氟甲基)苯硼酸
• 英文名称: 3-methoxy-5-trifluoromethylphenyl boronic acid
• 英文别名: 3-Methoxy-5-(trifluoromethyl)phenylboronic acid；[3-methoxy-5-(trifluoromethyl)phenyl]boronic acid
• CAS: 871332-97-7
• 化学式: C₈H₈BF₃O₃
• mdl: MFCD08056362
• 分子量: 219.956
• InChiKey: GKEMDZIGTOAZRK-UHFFFAOYSA-N

物化性质

• 熔点：
  159-162

计算性质

• 辛醇/水分配系数(LogP)：
  2.27
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Methoxy-5-trifluoromethylphenylboronic acid
Product Name:
Synonyms: 3-Methoxy-5-(trifluoromethyl)phenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-Methoxy-5-trifluoromethylphenylboronic acid
Ingredient name:
CAS number: 871332-97-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H8BF3O3
Molecular weight: 220.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲氧基-5-三氟甲基苯硼酸 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  芳烃硼试剂与sp3-碳亲核试剂的氧化偶联：乙醇酸Chan–Evans–Lam反应

  摘要：

  报道了一种用于活化的亚甲基物质的芳基化的通用的新氧化方法。在温和的反应条件下（室温至40°C），Cu（OTf）2介导功能化的芳基硼物种与各种稳定的sp 3-亲核试剂的选择性偶联。丙二酸叔丁酯和酰胺基酯可用作底物以生成四元中心。作为传统交叉偶联或S N Ar方案的补充，在卤素亲电试剂（包括芳基溴化物和碘化物）存在下，该转化过程具有化学选择性。带有酰胺基，磺酰基基和膦酰基基团的底物不适合在温和的Hurtley型条件下偶联，是合适的反应伙伴。

  DOI：

  10.1002/anie.201510558
• 作为产物：
  描述：

  2-(3-甲氧基-5-三氟甲基-苯基)-4,4,5,5-四甲基-[1,3,2]二噁硼烷 在 sodium periodate 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 17.5h， 生成 3-甲氧基-5-三氟甲基苯硼酸
  参考文献：
  名称：

  芳烃通过连续的铱催化的硼化和铜催化的偶联反应生成苯胺和芳基醚。

  摘要：

  [反应：见正文] N-烷基苯胺和N-芳基苯胺是通过铱催化的硼化和铜催化的与胺偶联的两步序列由芳烃合成的。通过芳烃硼化的相关顺序，然后与酚偶联，获得二芳基醚。特别地，通过用间位取代的芳烃起始该序列来制备3，5-二取代的芳基胺和芳基醚。

  DOI：

  10.1021/ol062902w

文献信息

• [EN] SUBSTITUTED 3, 4 - DIHYDRO - 2H - PYRIDO [1, 2 -A] PYRAZINE - 1, 6 - DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS DE 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE SUBSTITUÉS POUVANT ÊTRE UTILISÉS POUR LE TRAITEMENT DE (ENTRE AUTRES) LA MALADIE D'ALZHEIMER
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2013171712A1

  公开（公告）日：2013-11-21

  The present invention is concerned with novel substituted 3,4-dihydro-2H-pyrido[1,2- a]pyrazine-1,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, R5, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及新颖的Formula (I)中的取代3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物，其中R1、R2、R3、R4、R5、Z和X的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新颖化合物的方法，包括将这些化合物作为活性成分的药物组合物，以及将这些化合物用作药物的用途。
• Arenes to Anilines and Aryl Ethers by Sequential Iridium-Catalyzed Borylation and Copper-Catalyzed Coupling
  作者：C. Christoph Tzschucke、Jaclyn M. Murphy、John F. Hartwig

  DOI：10.1021/ol062902w

  日期：2007.3.1

  N-arylanilines were synthesized from arenes by a two-step sequence of iridium-catalyzed borylation and copper-catalyzed coupling with amines. Diaryl ethers were obtained by a related sequence of arene borylation, followed by coupling with phenols. In particular, 3,5-disubstituted arylamines and aryl ethers were prepared by initiating this sequence with meta-substituted arenes.

  [反应：见正文] N-烷基苯胺和N-芳基苯胺是通过铱催化的硼化和铜催化的与胺偶联的两步序列由芳烃合成的。通过芳烃硼化的相关顺序，然后与酚偶联，获得二芳基醚。特别地，通过用间位取代的芳烃起始该序列来制备3，5-二取代的芳基胺和芳基醚。
• 1-Thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives as antitumor agents
  作者：Alan B. Cooper、Stephane Ciblat、Gerald Shipps、Jedd Levine、Matthew Kostura、Vibha Oza、Lea Constantineau-Forget、Martin Dery、Chantal Grand-Maitre、Nicolas Bruneau-Latour、Edith Bellavance、Michael Patane、Arshad Siddiqui、Michael Luther

  DOI：10.1016/j.bmcl.2017.08.003

  日期：2017.9

  A class of substituted 1-thiazol-2-yl-N-3-methyl-1H-pyrozole-5-carboxylic acid derivatives was found to have potent anti-proliferative activity against a broad range of tumor cell lines. A compound from this class (14) was profiled across a broad panel of hematologic and solid tumor cancer cell lines demonstrating cell cycle arrest at the G0/G1 interphase and has potent anti-proliferative activity

  发现一类取代的1-噻唑-2-基-N-3-甲基-1H-吡咯-5-羧酸衍生物对多种肿瘤细胞系具有有效的抗增殖活性。此类化合物（14）在广泛的血液学和实体瘤癌细胞系中进行了分析，证明其在G0 / G1间期具有细胞周期停滞，并且对不同类型的精选癌细胞具有强大的抗增殖活性没有观察到对正常人细胞的影响。一个例子是对人B细胞淋巴瘤细胞系（BJAB）的选择性抑制。化合物14是口服生物利用的，并且在小鼠中耐受性良好。讨论了这一系列化合物的合成和结构活性关系（SAR）。
• NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：Woo Byoung Young

  公开号：US20110152318A1

  公开（公告）日：2011-06-23

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

  本发明涉及一种新型化合物，其异构体或其药学上可接受的盐作为vanilloid受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂；以及包含该化合物的制药组合物。本发明提供了一种用于预防或治疗疾病的制药组合物，例如疼痛、偏头痛、关节痛、神经痛、神经病、神经损伤、皮肤疾病、膀胱过敏、肠易激综合症、排便紧迫、呼吸系统疾病、皮肤、眼或黏膜刺激、胃十二指肠溃疡、炎症性疾病、耳病、心脏病等疾病。
• Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
  申请人：Woo Byoung Young

  公开号：US08691855B2

  公开（公告）日：2014-04-08

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

  本发明涉及一种新型化合物，其异构体或药学上可接受的盐作为vanilloid受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂；以及包含该化合物的制药组合物。本发明提供了一种预防或治疗疾病的制药组合物，如疼痛、偏头痛、关节痛、神经痛、神经病、神经损伤、皮肤疾病、膀胱过敏、肠易激综合征、排便紧迫、呼吸系统疾病、皮肤、眼部或粘膜刺激、胃十二指肠溃疡、炎症性疾病、耳病、心脏病等。